Andreas Melmer1, Linda Fineder2, Claudia Lamina2, Barbara Kollerits2, Benjamin Dieplinger3, Ioana Braicu4, Jalid Sehouli4, Isabelle Cadron5, Ignace Vergote5, Sven Mahner6, Alain G Zeimet7, Dan Cacsire Castillo-Tong8, Christoph F Ebenbichler9, Robert Zeillinger8, Hans Dieplinger10. 1. Division of Genetic Epidemiology, Department of Medical Genetics, Molecular and Clinical Pharmacology, Innsbruck Medical University, Austria; Department of Internal Medicine, Innsbruck Medical University, Austria. 2. Division of Genetic Epidemiology, Department of Medical Genetics, Molecular and Clinical Pharmacology, Innsbruck Medical University, Austria. 3. Department of Laboratory Medicine, Konventhospital Barmherzige Brüder, Linz, Austria. 4. Department of Gynecology, Campus Virchow-Klinikum, Charité University Hospital, European Competence Center for Ovarian Cancer Berlin, Germany. 5. Division of Gynecological Oncology, Department of Obstetrics and Gynecology and Leuven Cancer Institute, Leuven University Hospitals, Katholieke Universiteit of Leuven, Belgium. 6. Department of Gynecology, Hamburg-Eppendorf University Medical Center, University Cancer Center Hamburg-Eppendorf (UCCH), Germany. 7. Department of Gynecology and Obstetrics, Innsbruck Medical University, Austria. 8. Department of Obstetrics and Gynecology, Molecular Oncology Group, Vienna Medical University, Austria. 9. Department of Internal Medicine, Innsbruck Medical University, Austria. 10. Division of Genetic Epidemiology, Department of Medical Genetics, Molecular and Clinical Pharmacology, Innsbruck Medical University, Austria; Vitateq Biotechnology GmbH, Innsbruck, Austria. Electronic address: hans.dieplinger@i-med.ac.at.
Abstract
OBJECTIVE: Comparative proteomics identified the plasma protein afamin as potential biomarker for ovarian cancer (OC). Significantly decreased afamin plasma concentrations in pre-therapeutic OC patients reconstituted to control values after successful tumor surgery. This study evaluates the association of afamin with survival and response to therapy in serous OC patients within the OVCAD consortium project. METHODS: We measured afamin in 215 pre-therapeutic plasma samples, 246 tumor lysates and 109 plasma samples taken 6months after finishing platinum-based chemotherapy. Differences in afamin plasma concentrations among FIGO stages were tested by Kruskal-Wallis test; association of afamin concentrations with overall and progression-free survival was evaluated using Kaplan-Meier survival plots and multivariate adjusted COX regression analysis. RESULTS: Pre-therapeutic afamin correlated significantly with FIGO stages (p=0.012) and was lower in the presence of metastases (p=0.013) and poorly differentiated OC in patients responding to therapy (p=0.016). Afamin ≥48.0mg/L was also associated with a lower hazard ratio for recurrent disease as compared to afamin <48.0mg/L (p=0.007). Post-therapeutic afamin ≥48mg/L was positively correlated with overall (p<0.001) and progression-free (p=0.012) survival and was lower in non-responders than in responders (p=0.048). Thus, afamin returned post-therapeutically to values of healthy controls in responders (p<0.001) but not in non-responders (p=0.114). Afamin in tumor lysates was lower in poorly differentiated OC than in G 1+2 tumors (p=0.041). Higher afamin concentrations in tumor lysates were associated with increased overall survival (p=0.003). CONCLUSION: These data indicate that afamin is associated with therapy response and survival rate in advanced OC patients.
OBJECTIVE: Comparative proteomics identified the plasma protein afamin as potential biomarker for ovarian cancer (OC). Significantly decreased afamin plasma concentrations in pre-therapeutic OC patients reconstituted to control values after successful tumor surgery. This study evaluates the association of afamin with survival and response to therapy in serous OC patients within the OVCAD consortium project. METHODS: We measured afamin in 215 pre-therapeutic plasma samples, 246 tumor lysates and 109 plasma samples taken 6months after finishing platinum-based chemotherapy. Differences in afamin plasma concentrations among FIGO stages were tested by Kruskal-Wallis test; association of afamin concentrations with overall and progression-free survival was evaluated using Kaplan-Meier survival plots and multivariate adjusted COX regression analysis. RESULTS: Pre-therapeutic afamin correlated significantly with FIGO stages (p=0.012) and was lower in the presence of metastases (p=0.013) and poorly differentiated OC in patients responding to therapy (p=0.016). Afamin ≥48.0mg/L was also associated with a lower hazard ratio for recurrent disease as compared to afamin <48.0mg/L (p=0.007). Post-therapeutic afamin ≥48mg/L was positively correlated with overall (p<0.001) and progression-free (p=0.012) survival and was lower in non-responders than in responders (p=0.048). Thus, afamin returned post-therapeutically to values of healthy controls in responders (p<0.001) but not in non-responders (p=0.114). Afamin in tumor lysates was lower in poorly differentiated OC than in G 1+2 tumors (p=0.041). Higher afamin concentrations in tumor lysates were associated with increased overall survival (p=0.003). CONCLUSION: These data indicate that afamin is associated with therapy response and survival rate in advanced OC patients.
Authors: Michael Hubalek; Hannes Buchner; Manfred G Mörtl; Dietmar Schlembach; Berthold Huppertz; Branka Firulovic; Wolfgang Köhler; Erich Hafner; Benjamin Dieplinger; Ludwig Wildt; Hans Dieplinger Journal: Clin Chim Acta Date: 2014-04-24 Impact factor: 3.786
Authors: Stanislav Naryzhny; Natalia Ronzhina; Elena Zorina; Fedor Kabachenko; Nikolay Klopov; Victor Zgoda Journal: Int J Mol Sci Date: 2022-09-21 Impact factor: 6.208
Authors: Benjamin Dieplinger; Margot Egger; Christian Gabriel; Werner Poelz; Elisabeth Morandell; Beata Seeber; Florian Kronenberg; Meinhard Haltmayer; Thomas Mueller; Hans Dieplinger Journal: Clin Chim Acta Date: 2013-08-24 Impact factor: 3.786